As of 2026-01-02, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (0.89) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.80 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -111.4%.
The range of the Relative Valuation is (0.91) - (1.04) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.8x - 24.8x | 24.6x |
| Forward P/E multiples | 17.8x - 25.2x | 18.0x |
| Fair Price | (0.91) - (1.04) | (0.89) |
| Upside | -111.7% - -113.3% | -111.4% |
| Date | P/E |
| 2025-12-26 | -182.98 |
| 2025-12-24 | -184.66 |
| 2025-12-23 | -180.59 |
| 2025-12-22 | -182.50 |
| 2025-12-19 | -177.71 |
| 2025-12-18 | -174.83 |
| 2025-12-17 | -170.99 |
| 2025-12-16 | -179.15 |
| 2025-12-15 | -182.03 |
| 2025-12-12 | -181.55 |
| 2025-12-11 | -181.79 |
| 2025-12-10 | -183.70 |
| 2025-12-09 | -183.22 |
| 2025-12-08 | -184.66 |
| 2025-12-05 | -182.03 |
| 2025-12-04 | -187.78 |
| 2025-12-03 | -188.26 |
| 2025-12-02 | -171.71 |
| 2025-12-01 | -170.99 |
| 2025-11-28 | -172.19 |
| 2025-11-26 | -170.27 |
| 2025-11-25 | -164.28 |
| 2025-11-24 | -163.80 |
| 2025-11-21 | -167.16 |
| 2025-11-20 | -168.60 |
| 2025-11-19 | -166.20 |
| 2025-11-18 | -167.88 |
| 2025-11-17 | -168.60 |
| 2025-11-14 | -169.79 |
| 2025-11-13 | -165.48 |
| 2025-11-12 | -172.19 |
| 2025-11-11 | -173.39 |
| 2025-11-10 | -172.67 |
| 2025-11-07 | -170.03 |
| 2025-11-06 | -168.60 |
| 2025-11-05 | -171.95 |
| 2025-11-04 | -162.12 |
| 2025-11-03 | -164.52 |
| 2025-10-31 | -175.55 |
| 2025-10-30 | -173.87 |
| 2025-10-29 | -175.31 |
| 2025-10-28 | -173.63 |
| 2025-10-27 | -175.31 |
| 2025-10-24 | -172.67 |
| 2025-10-23 | -172.43 |
| 2025-10-22 | -169.79 |
| 2025-10-21 | -167.52 |
| 2025-10-20 | -166.20 |
| 2025-10-17 | -159.00 |
| 2025-10-16 | -161.16 |